Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Interesting results from a 1L trial of ET+ribo+ trastuzumab for HR+/HER2+ MBC (n=90). ORR 61%, mPFS 30 months. Confirming what we’re realizing more and more: patients with triple-positive metastatic disease NEED to receive a CDK4/6 inhibitor at part of their 1L treatment.“
More posts featuring ASCO25.
